Author:
Anggraini Rahayu,Wulandari Devyana Dyah,Herdiani Novera,Wijayanti Lono,Rohmawati Riska
Publisher
Atlantis Press International BV
Reference9 articles.
1. Brosstad, F. (1993). Von Willebrand’s disease--gene, molecule, clinical findings, treatment. In Tidsskrift for den Norske laegeforening (Vol. 113, Issue 23).
2. Carnevale, S., Rodríguez, M. I., Santillán, G., Labbé, J. H., Cabrera, M. G., Bellegarde, E. J., Velásquez, J. N., Trgovcic, J. E., & Guarnera, E. A. (2001). Immunodiagnosis of human fascioliasis by an enzyme-linked immunosorbent assay (ELISA) and a micro-ELISA. Clinical and Diagnostic Laboratory Immunology.https://doi.org/10.1128/CDLI.8.1.174-177.2001
3. Doevelaar, A. A. N., Bachmann, M., Hölzer, B., Seibert, F. S., Rohn, B. J., Bauer, F., Witzke, O., Dittmer, U., Bachmann, M., Yilmaz, S., Dittmer, R., Schneppenheim, S., Babel, N., Budde, U., & Westhoff, T. H. (2021). von Willebrand Factor Multimer Formation Contributes to Immunothrombosis in Coronavirus Disease 2019. Critical Care Medicine, 49(5). https://doi.org/10.1097/CCM.0000000000004918
4. Luo, G. P., Ni, B., Yang, X., & Wu, Y. Z. (2012). Von Willebrand factor: More than a regulator of hemostasis and thrombosis. In Acta Haematologica. https://doi.org/10.1159/000339426
5. Mahat, M., Abdullah, W. Z., & Che Hussin, C. M. (2014). Conventional rapid latex agglutination in estimation of von willebrand factor: Method revisited and potential clinical applications. Journal of Immunology Research. https://doi.org/10.1155/2014/850810